TaeWoong Medical USA, a leader in minimally invasive gastrointestinal (GI) solutions, is pleased to announce the signing of a Letter of Intent (LOI) with BiBBInstruments AB, the Swedish developer of the EndoDrill® platform—marking a major step toward U.S. commercialization of EndoDrill® GI, the world’s first powered biopsy instrument for endoscopy.
The LOI outlines a strategic partnership aimed at launching EndoDrill® GI in select U.S. hospitals in Fall 2025, followed by a nationwide rollout in 2026. This collaboration will kick off with joint customer demonstrations at Digestive Disease Week (DDW) 2025, the largest global event in GI medicine.
"EndoDrill® GI represents a new era in diagnostic endoscopy," said Minsoo Seo, CEO, TaeWoong Medical USA. "As a company committed to advancing patient care through innovation, we see EndoDrill® as a natural complement to our existing therapeutic endoscopic portfolio, including the EUS-guided RFA systems and Niti-S™ stent line."
The partnership builds on BiBB’s recent momentum, including FDA clearance of EndoDrill® GI, encouraging early clinical results, and the company’s first U.S. sale to a major university hospital in January 2025.
"TaeWoong Medical USA’s strong presence and reputation in therapeutic EUS make them an ideal partner as we scale EndoDrill® GI in the U.S.," said Fredrik Lindblad, CEO of BiBBInstruments AB. "Together, we can bring high-precision, powered biopsy to more clinicians and patients across the country."
The EndoDrill® GI system is designed for EUS-guided biopsy of GI lesions, including the pancreas, stomach, lymph nodes and liver, offering improved tissue acquisition with precision and efficiency.
Attendees at DDW who would like to learn more about EndoDrill® GI are invited to visit TaeWoong Medical USA at Booth #1317 in the San Diego Convention Center, open from 9:30 AM to 4:00 PM, May 4–6.
About TaeWoong Medical USA
TaeWoong Medical USA is a fast-growing distributor of innovative gastrointestinal medical devices, committed to improving patient care across the United States. As the exclusive U.S. partner of TaeWoong Medical Co., Ltd. — a global leader in the development and manufacturing of advanced medical technologies — we offer a comprehensive portfolio including esophageal, biliary and colonic stents, RFA (radiofrequency ablation) systems and endoscopic accessories. Based in California, we focus on rapid delivery, clinical excellence and building strong relationships with healthcare professionals nationwide. Our mission is to bring world-class solutions to the U.S. healthcare market with a deep commitment to innovation, quality and service. Learn more at www.taewoongusa.com.
About BiBBInstruments AB
BiBBInstruments AB is a pioneer in powered endoscopic biopsy. Its flagship EndoDrill® system, FDA-cleared and CE-marked, enables high-precision tissue acquisition across a range of GI and pulmonary indications. Based in Lund, Sweden, BiBB is focused on transforming cancer diagnostics with advanced biopsy technology. Learn more at www.bibbinstruments.com.